Ranitidine Recalls Continue for NDMA Contamination
Since late September, 10 recalls have been issued by manufacturers of generic ranitidine tablets, capsules, and syrups because of contamination by N-nitrosodimethylamine (NDMA). Three recalls have occurred so far in November. The FDA detected NDMA, considered a probable carcinogen, in ranitidine products in September following identification of widespread NDMA contamination in generic angiotensin II receptor blockers. Read more.